Gene-targeted therapies for the central nervous system

Timothy M. Miller, Richard A. Smith, Holly Kordasiewicz, Brian K. Kaspar

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations

Abstract

The identification of the genes and proteins involved in many neurodegenerative diseases1 offers the exciting possibility of modifying those disease-linked proteins to develop novel, targeted therapies for diseases such as amyotrophic lateral sclerosis (ALS) or Huntington disease. In many of these diseases, the simplest modification - decreasing the amount of the offending protein - may represent a potent therapy. This realization, coupled with great strides in the techniques for decreasing specific proteins, has set the stage for moving these new therapies from animal models to clinical trials in the near future.

Original languageEnglish
Pages (from-to)447-451
Number of pages5
JournalArchives of neurology
Volume65
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Dive into the research topics of 'Gene-targeted therapies for the central nervous system'. Together they form a unique fingerprint.

Cite this